You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Taltz ® (ixekizumab) injection
80 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Has lymphoma been reported with Taltz® (ixekizumab)?
The incidence rate of lymphoma across 17 ixekizumab trials conducted in adult patients with plaque psoriasis was 0.02 per 100 patient-years as of March 2022.
Treatment-Emergent Malignancies Including Lymphoma in Psoriasis Clinical Trials
Across 17 pooled psoriasis trials conducted in adult patients (N=6892), accounting for 18,025.7 patient-years (PYs) of total ixekizumab exposure as of the March 2022 database lock, the treatment-emergent lymphomas reported based on Medical Dictionary for Regulatory Activities (MedDRA) preferred terms included
- B-cell lymphoma (n=1, 0%)
- diffuse large B-cell lymphoma (n=1, 0%)
- Hodgkin's disease (n=1, 0%)
- Hodgkin's disease mixed cellularity stage unspecified (n=1, 0%), and
- Non-Hodgkin's lymphoma (n=1, 0%).1
Treatment-Emergent Malignancies Including Lymphoma in Psoriatic Arthritis Clinical Trials
Four pooled psoriatic arthritis trials (N=1401, accounting for 2247.7 PYs of total ixekizumab exposure as of the March 2022 database lock), reported no treatment-emergent lymphomas based on MedDRA preferred terms.1
Treatment-Emergent Malignancies Including Lymphoma in Axial Spondyloarthritis Trials
Four axial spondyloarthritis trials that include patients with ankylosing spondylitis/radiographic axial spondyloarthritis and nonradiographic axial spondyloarthritis (N=932, accounting for 2097.7 PYs of total ixekizumab exposure as of the March 2022 database lock), reported no treatment-emergent lymphomas based on MedDRA preferred terms.1
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Deodhar A, Blauvelt A, Lebwohl M, et al. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis Res Ther. 2024;26(1):49. https://doi.org/10.1186/s13075-023-03257-7
3Merola JF, Papp KA, Deodhar A, et al. Ixekizumab and malignant neoplasms: a pooled analysis of data from 25 randomized clinical trials. JAMA Dermatol. Published online July 9, 2025. https://doi.org/10.1001/jamadermatol.2025.2056
Date of Last Review: September 09, 2025